Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece - the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).

Tsironis G, Koutsoukos K, Athanasakis K, Tsiara A, Tzannis K, Gerolympou M, Visvikis A, Oikonomopoulos G, Kollia A, Giannopoulou E, Dimitra M, Kostouros E, Papatsoris A, Dellis A, Stravodimos K, Varkarakis I, Samantas E, Aravantinos G, Kentepozidis N, Christodoulou C, Bozionelou V, Dimopoulos MA, Bamias A.

Expert Rev Pharmacoecon Outcomes Res. 2018 Nov 10. doi: 10.1080/14737167.2019.1546121. [Epub ahead of print]

PMID:
30417707
2.

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib.

Koutsoukos K, Bamias A, Tzannis K, Espinosa MontaƱo M, Bozionelou V, Christodoulou C, Stefanou D, Kalofonos H, Duran I, Papazisis K.

Onco Targets Ther. 2017 Oct 6;10:4885-4893. doi: 10.2147/OTT.S141260. eCollection 2017.

3.

Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG).

Bamias A, Peroukidis S, Stamatopoulou S, Tzannis K, Koutsoukos K, Andreadis C, Bozionelou V, Pistalmatzian N, Papatsoris A, Stravodimos K, Varthalitis I, Karamouzis M, Milaki G, Agorastos A, Kentepozidis N, Androulakis N, Bompolaki I, Kalofonos H, Mavroudis D, Dimopoulos MA.

Clin Genitourin Cancer. 2016 Apr;14(2):e153-9. doi: 10.1016/j.clgc.2015.09.009. Epub 2015 Sep 25.

PMID:
26437909
4.

Dedifferentiated paratesticular liposarcoma with osseous metaplasia.

Chondros K, Heretis I, Papadakis M, Bozionelou V, Mavromanolakis E, Chondros N, Mamoulakis C.

Case Rep Urol. 2015;2015:965876. doi: 10.1155/2015/965876. Epub 2015 Apr 16.

5.

Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.

Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25. doi: 10.1007/s00280-014-2598-2. Epub 2014 Oct 26.

PMID:
25344760
6.

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.

Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2012 Jul;70(1):169-76. doi: 10.1007/s00280-012-1901-3. Epub 2012 Jun 6.

PMID:
22669571
7.

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.

Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, Mavroudis D, Georgoulias V.

Br J Cancer. 2012 Jun 5;106(12):1917-25. doi: 10.1038/bjc.2012.202.

8.

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D.

Ann Oncol. 2012 Jul;23(7):1744-50. doi: 10.1093/annonc/mds020. Epub 2012 Feb 29.

PMID:
22377561
9.

Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.

Samonis G, Koutsounaki E, Karageorgopoulos DE, Mitsikostas P, Kalpadaki C, Bozionelou V, Bompolaki I, Sgouros J, Taktikou V, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1389-98. doi: 10.1007/s10096-011-1454-0. Epub 2011 Oct 31.

PMID:
22037822
10.

Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.

Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, Mavroudis D, Georgoulias V.

Ann Oncol. 2011 Nov;22(11):2448-55. doi: 10.1093/annonc/mdq772. Epub 2011 Mar 10.

PMID:
21393380
11.

A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.

Kotsakis A, Hatzidaki D, Vamvakas L, Vardakis N, Kalykaki A, Bozionelou V, Androulakis N, Kalbakis K, Saridaki Z, Georgoulias V, Agelaki S.

Anticancer Res. 2010 Oct;30(10):4335-42.

PMID:
21036760
12.

Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.

Polyzos A, Kalbakis K, Kentepozidis N, Giassas S, Kalykaki A, Vardakis N, Bozionelou V, Saloustros E, Kontopodis E, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2011 Jul;68(1):217-23. doi: 10.1007/s00280-010-1475-x. Epub 2010 Oct 5.

PMID:
20922389
13.

Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.

Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Feb;67(2):361-8. doi: 10.1007/s00280-010-1329-6. Epub 2010 Apr 29.

PMID:
20428874
14.

A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.

Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2009 Sep;64(4):785-91. doi: 10.1007/s00280-009-0928-6. Epub 2009 Jan 22.

PMID:
19159931
15.

A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.

Saridaki Z, Bozionelou V, Kentepozidis N, Kotsakis A, Vardakis N, Kalykaki A, Gioulbasanis I, Karampeazis A, Vamvakas L, Georgoulias V, Mavroudis D.

Oncology. 2007;72(1-2):45-50. Epub 2007 Nov 12. Erratum in: Oncology. 2007;73(5-6):406. Karabeazis, Athanasios [corrected to Karampeazis, Athanasios].

PMID:
17998790
16.

Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.

Gkioulbasanis I, Souglakos J, Vardakis N, Kotsakis A, Saridaki Z, Kentepozidis N, Polyzos A, Giassas S, Ignatiadis M, Bozionelou V, Christophylakis C, Georgoulias V.

J BUON. 2007 Apr-Jun;12(2):197-202.

PMID:
17600872
17.

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.

Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A, Nikolaidou M, Kentepozidis N, Giassas S, Marselos M, Georgoulias V, Mavroudis D.

Br J Cancer. 2007 Jul 2;97(1):43-9. Epub 2007 Jun 5.

18.

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.

Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D.

Ann Oncol. 2007 May;18(5):851-8. Epub 2007 Feb 14. Erratum in: Ann Oncol. 2007 Nov;18(11):1916.

PMID:
17301075
19.

Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes.

Stathopoulos EN, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D, Georgoulias V.

Ann Oncol. 2005 Feb;16(2):240-6.

PMID:
15668277
20.

High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.

Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, Agelaki S, Malas K, Bozionelou V, Georgoulias V.

Lung Cancer. 2004 Jun;44(3):363-8.

PMID:
15140550

Supplemental Content

Loading ...
Support Center